Ixico Regulatory News (IXI)

IXICO PLC

("IXICO or the "Company")

TRADING UPDATE

Revenue anticipated to be ahead of expectations for the year ending 30 September 2026

Revenue now expected to represent c.22% growth compared to FY 2025

07 July 2026: IXICO plc (AIM: IXI), IXICO, a global leader in neuroscience imaging and biomarker analytics, using its AI-driven platform to help advance drug development and diagnostics in neurological disorders, today provides a trading update for its current year which ends on 30 September 2026 ("FY 2026").

The Company anticipates FY 2026 revenues to be at least £8.0 million, ahead of existing market expectations and representing an increase of c.22% on FY 2025 revenues. This update, a consequence of strong trading across an increasingly diverse client base combined with contract extensions, replaces the original forecast of £7.5 million, previously representing a 15% uplift on FY25 revenues.

Bram Goorden, CEO of IXICO, said: "The strong performance has been driven by a continued uplift in contract wins, contract extensions, and revenue diversification. The results are a direct result of a plan put in place in 2024 and clearly demonstrating the fruits of that strategy as it matures. We will continue to deliver innovative differentiated scientific products, services and technology that position IXICO at the forefront of neuroscience."

Ends

The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the UK version of the EU Market Abuse Regulation 596/2014 which is part of UK law by virtue of the European Union (Withdrawal) Act 2018, as amended and supplemented from time to time. Upon the publication of this announcement, this inside information is now considered to be in the public domain.

For further information please contact:

About IXICO www.IXICO.com

IXICO is a global leader in neuroscience imaging and biomarker analytics, using its proprietary AI-driven platform to help advance the treatment of neurological disorders and reduce the uncertainties associated with drug discovery, development and monitoring. As a key part of the global neurological disease research community, the Company has built a global reputation and 20-year track record as an end-to-end Imaging Contract Research Organisation (iCRO) working with leading pharma companies, innovative biotechs, disease consortia and non-profit organisations. IXICO has supported hundreds of neurological clinical trials, analysed hundreds of thousands of scans and built an expansive network of expert imaging centres around the world.

The IXITM platform is tailor-made for neurological disease, reliably processing data from global trials, precisely measuring key imaging biomarkers associated with the identification, progression and treatment of diseases such as Alzheimer's, Huntington's and Parkinson's. Image data is interrogated by the platform and IXICO's expert scientists translating complex data into clinically meaningful while minimizing data variability and increasing reproducibility.